PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22288300-6	2011	After 3 months of olmesartan treatment, the mean serum cystatin C (p: 0.001, 0.023 and 0.018 respectively), systolic (p: 0.001, 0.001 and 0.001 respectively) and diastolic BP levels (p: 0.001, 0.001 and 0.001 respectively) decreased in all groups.	olmesartan	18-28	cystatin C	Homo sapiens	55-65	
22288300-10	2011	Olmesartan treatment led to a decrease of cystatin C level.	olmesartan	0-10	cystatin C	Homo sapiens	42-52	
19521888-10	2009	Our findings indicate that olmesartan medoxomil decreases serum cystatin C levels, urine ACR and reduces LVH in patients with hypertension.	olmesartan	27-37	cystatin C	Homo sapiens	64-74	
19521888-11	2009	To our knowledge, this study is the first to show that olmesartan medoxomil decreases serum cystatin C levels, indicating that in patients with essential hypertension it may counteract end organ damage.	olmesartan	55-65	cystatin C	Homo sapiens	92-102	
22288300-0	2011	Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.	olmesartan	10-20	cystatin C	Homo sapiens	30-40	
22288300-1	2011	AIM: We aimed to investigate whether Olmesartan had an effect on cystatin C levels in hypertensive patients, and evaluate its correlation with blood pressure (BP).	olmesartan	37-47	cystatin C	Homo sapiens	65-75	
19521888-3	2009	Our goal was to evaluate the effect of olmesartan medoxomil on cystatin C levels and left ventricular hypertrophy (LVH) in patients with hypertension.	olmesartan	39-49	cystatin C	Homo sapiens	63-73